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Background: Our prior study showed that resveratrol could suppress infarct volume and exert neuroprotective effect on
rats subjected to focal cerebral ischemia (FCI) injury. Recently, it has been reported in some literature that resveratrol
protects the spinal cord, kidney, and heart from ischemia-reperfusion injury through upregulation of nitric oxide (NO).
Therefore, this study was designed to investigate the role of nitric oxide on the neuroprotective mechanisms of resveratrol
on rats after FCI injury.
Methods: The FCI injury was induced by the middle cerebral artery (MCA) occlusion for 1 hour and then a 24-hour
reperfusion followed in the anesthetized Long-Evans rats. Resveratrol was intravenously injected after 1 hour MCA
occlusion.
Results: Treatment of resveratrol (0.1 and 1 g/kg) decreased the lactate dehydrogenase (LDH) in plasma and
malondialdehyde (MDA) in FCI injury brain tissue, whereas the level of NO in plasma was increased. In addition,
resveratrol downregulated protein and mRNA expression of inducible nitric oxide synthase (iNOS), and upregulated
protein and mRNA expression of endothelial nitric oxide synthase (eNOS), while the expression of protein and mRNA
of neuronal nitric oxide synthase (nNOS) was unchanged. Pretreatment with NG-nitro-L-arginine methyl ester
(L-NAME, the nonselective NOS inhibitor) or L-N5-(1-iminoethyl)-ornithine (L-NIO, the eNOS selective inhibitor)
completely blocked the effect of resveratrol in decreasing infarction volumes.
Conclusions: This study demonstrated the important role of NO in the neuroprotective effect of resveratrol in FCI injury.
(J Vasc Surg 2007;46:346-53.)
Clinical Relevance: Ischemic brain damage is the major cause of permanent disability in young adults. It has been
suggested that up to 80% of all strokes result from ischemic damage in the middle cerebral artery area. The potential for
clinical application of pharmacological agents has generated enormous interest in identifying the underlying intracellular
signaling pathways and to develop therapeutic strategies that can benefit ischemic stroke injury in patients. This study
explored the possible involvement of nitric oxide in neuroprotective effect of resveratrol on focal cerebral ischemia injury.Nitric oxide (NO), a cellular signaling molecule, is
synthesized during the stoichiometric conversion of
L-arginine to L-citrulline in the presence of oxygen and
nicotinamide adenine dinucleotide phosphate (NADPH),
which is catalyzed by nitric oxide synthase (NOS).1 Three
isoforms of NOS that were named by the tissue are first
cloned. Neuronal NOS (nNOS; 157 kDa) and endothelial
From the Department of Anesthesiology, College of Medicine, Buddhist
Tzu-Chi University and Hospital, Taipei;a the National Taiwan Univer-
sity, Taipei;b the Department of Life Science, College ofMedicine, Chang
Gung University Tao-Yuan;c the School of Post-Baccalaureate Chinese
Medicine, China Medical University and Department of Acupuncture,
China Medical University Hospital, Taichung;d the Neural Regeneration
Laboratory, Department of Neurosurgery, Neurological Institute, Taipei
Veterans General Hospital, Taipei;e and theDepartment of Pharmacology
and Institute of Medicine, College of Medicine, Chung Shan Medical
University, Taichung.f
Competition of interest: none.
Reprint requests: Shiang-Suo Huang, PhD, Department of Pharmacology
and Institute of Medicine, College of Medicine, Chung Shan Medical
University No110, Sec 1, Chien Kuo N Rd, Taichung, Taiwan (e-mail:
sshuang@csmu.edu.tw).
0741-5214/$32.00
Copyright © 2007 by The Society for Vascular Surgery.
doi:10.1016/j.jvs.2007.04.044
346NOS (eNOS; 140 kDa) are constitutively expressed and
calcium-dependent, whereas inducible NOS (iNOS; 135
kDa) is expressed after immunologic challenge and neuro-
nal injury and is calcium-dependent under most circum-
stances.2 NO has a variety of physiological and pathological
effects in biological systems.3 Under normal physiological
conditions, NO is an important endogenous vasodilator
that can regulate cerebral blood flow and mediate vascular
response to a diverse group of stimulations.4 In addition,
NO can inhibit platelet aggregation5 and inhibit both
platelet6 and polymorphonuclear neutrophil (PMN)7 ad-
hesion to the vascular endothelium. Several lines of evi-
dence have reported that NO donor or L-arginine exerts
neuroprotective effect in stoke models.8,9 The findings
indicate that NO donor, sodium nitroprusside, improves
blood flow and reduces tissue damage after focal cerebral
ischemia.8 In both normotensive and hypertensive animals,
L-arginine induces sustained cerebral blood flow increases
in normal brain as well as in a marginally perfused brain
region distal to middle cerebral artery (MCA) occlusion
and decreases infarction volume after MCA occlusion.9
Resveratrol, a polyphenol phytoalexin (trans 3,4=,5-
trihydroxystilbene), is abundantly available in a wide variety
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and constitutes one of the major components of red
wine.10 Resveratrol has been reported to have a host of
physiological effects, including the prevention of lipid per-
oxidation in human LDL,11 inhibition of arachidonate acid
metabolism,12 and platelet activity.13 Resveratrol was also
found to stimulate nitric oxide (NO) production in endo-
thelial cells to exert vasodilatory effect on blood vessels14
and to interfere with the release of inflammatory media-
tors by activated human polymorphonuclear leukocytes
(PMN), and down-regulate adhesion-dependent thrombo-
genic PMN functions.15 Resveratrol is considered as a
potential neuroprotective agent in treating acute scenarios
in focal cerebral ischemia (FCI) injury. Our previous study
showed that resveratrol could effectively suppress infarct
size from the damaging effects of FCI.16 Recently, resvera-
trol was found to protect spinal cord,17 kidneys,18 and
heart 19 from ischemia-reperfusion injury through upregu-
lation of NO.
On the basis of these findings, the purpose of this
experimental study was to determine the role of NO in the
neuroprotective effect of resveratrol on rats subjected to
FCI injury.
MATERIALS AND METHODS
Animals. The present investigation conforms to the
Guide for the Care and Use of Laboratory Animals pub-
lished by the US National Institute of Health (NIH publi-
cation No. 85-23, revised 1996). Male Long-Evans rats
(National Laboratory Animal Breeding and Research Cen-
ter) weighing 250 to 320 g were used throughout this
study. These animals were housed in a room with con-
trolled temperature (24  1°C) and humidity (55  5%)
under a 12:12 h light-dark cycle. They were allowed free
access to food and water.
Surgical procedure. Each rat was anesthetized with
halothane (1% to 3.5% in a mixture of 70% N2O and 30%
O2) with the use of a mask. Body temperature was main-
tained during surgery at 37  0.5°C with a heating pad
servo-controlled by a rectal probe. The right femoral artery
was cannulated with PE-50 polyethylene catheters for con-
tinuous monitoring of heart rate and mean arterial blood
pressure (MABP) by Statham P23 XL transducer and dis-
played on a Gould RS-3400 physiological recorder (Gould,
Cleveland, Ohio), and blood sampling for analysis of blood
gases by a blood gas analyzer (GEM-5300 Instrumentation
Laboratory Company, Lexington, Mass). In addition, the
right femoral vein was cannulated for drug administration.
Focal ischemic infarcts were made in the right lateral
cerebral cortex in the territory of the MCA. Both common
carotid arteries were exposed by midline anterior cervical
incision. The animal was placed in a lateral position, and a
skin incision was made at the midpoint between the right
lateral canthus and the anterior pinna. The temporal muscle
was retracted, and a small (3-mm diameter) craniectomy
was made at the junction of the zygoma and squamosal
bone using a drill (Dremel Multipro5395, Dremel,
Racine, Wis) cooled with saline solution. Using a dissectingmicroscope (OPMI-1, ZEISS, Carl Zeiss, Germany), the
dura was opened with fine forceps, and the right MCA was
ligated with 10-0 monofilament nylon ties. Both common
carotid arteries were then occluded by microaneurysm clips
for 1 hour. After removing the clips, return of flow was
visualized in the both common carotid arteries. However,
the right MCA ligature remained in place permanently.20
Infarct volume analysis. Twenty-four hours after ce-
rebral infarction, animals were anesthetized and killed by
rapid decapitation. Brain were removed, inspected visually
for the anatomy of theMCA and for signs of hemorrhage or
infection, immersed in cold saline solution for 10 minutes,
and sectioned into standard coronal slices (each 2-mm
thick) using a brain matrix slicer (Jacobowitz Systems,
Zivic-Miller Laboratories Inc, Allison Park, Pa). Slices were
placed in the vital dye 2,3,5-triphenyltetrazolium chloride
(TTC, 2%; Sigma, Sigma-Aldrich, St. Louis, Mo) at 37°C
in the dark for 30 minutes, followed by 10% formalin at
room temperature overnight. The outline of right and left
cerebral hemispheres as well as that of infarct tissue, which
was clearly visualized by a lack of TTC staining,20 was
outlined on the posterior surface of each slice using an
image analyzer (color image scanner, EPSON GT-9000,
connected to an image analysis system (AIS software, Im-
aging Research Inc, Brock University, Ontario, Canada)
run on a personal computer, AMD K6-2 3D 400. Infarct
volume was calculated as the sum of infarct area per slice
multiplied by slice thickness. Both the surgeon and image
analyzer operator were blinded to the treatment given each
animal.
Plasma lactate dehydrogenase (LDH) and NO
analysis. Cellular damage was evaluated by measuring the
LDH in plasma. Samples of arterial blood were drawn from
the femoral catheter at the end after 1 hourMCA occlusion
and 24 hour reperfusion, collected in heparinized tubes.
The blood was kept at 4°C until it was centrifuged at 2000
g for 15 min. The plasma was recovered and aliquots were
used for determination of LDH activity. LDH activity
was measured spectrophotometrically, according to the
method of Bergmeyer and Brent,21 by following the rate of
conversion of NADH to NAD, at 340 nm.
The deproteinized plasma samples were frozen and
kept until analysis. For measurement of NO, we em-
ployed the NO/ozone chemiluminescence technique
(NOA 280, Sievers Instruments, Boulder, Colo).22 The
detection of plasma NO level is based on its reaction with
ozone, which leads to the emission of red light. The
photons from this reaction are detected and transformed
to an electrical signal by a photomultiplier tube (PMT).
Due to the use of filters in front of the PMT, NO/O3
chemiluminescence recorded with the Sievers NOA 280
is highly specific for NO. The current from the PMT is
A/D converted and fed into a PC running the Asyst
software (Sievers NO Analysis Liquid Program). The
amount of light produced by NO/O3 chemilumines-
cence is proportional to the amount of NO
CGA
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the PMT current for each determination is proportional
to the amount of NO. This was verified before each
experiment by standard curves (1, 5, 10, 20, 40, 100
mol/L), which were produced using freshly prepared
solutions of sodium nitrite in distilled water, which was
reduced to NO in an equimolar manner by the reducing
agent. We chose to measure the level of nitrite or nitrate
on blood sample by using a reaction vessel containing a
reducing system (Vanadium [III] dissolved in 1 MHCl),
which the sample was injected and NO was generated
from nitrite or nitrate in an equimolar manner. A con-
tinuous stream of helium (99.999%) purged the resultant
NO from the reaction vessel to the chemiluminescence
chamber.
Western blot analysis. Rats were perfused with saline,
and the brains were prepared for Western blot analysis.
Brains tissue was homogenized in Laemmli lysis buffer
containing protease inhibitors (10 l/0.2 g tissue weight,
Sigma, St. Louis, Mo). Protein concentrations in each
sample solution were determined using a protein assay kit
(BCA kit; Pierce, Rockford, Ill), and the samples were
stored at 80°C until use. Aliquots containing 120 g of
protein were subjected to 10% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis and transferred to poly-
vinylidene difluoride membrane (IPVH00010; Millipore
Corp, Bedford, Mass). Western blot analysis of NOS pro-
tein was performed as previously described.23 Protein
bands were transferred to polyvinylidene difluoride mem-
brane (IPVH00010; Millipore Corp, Bedford, Mass) and
probed for iNOS (1:1000 [catalog no. N32020; Transduc-
tion Laboratories, Lexington, Ky]), nNOS (1:1000 [cata-
log no. N41520; Transduction Laboratories, Lexington,
Ky]), eNOS (1:1000 [catalog no. N30020; Transduction
Laboratories, Lexington, Ky]) and 1:2000 actin (sc-1616;
Santa Cruz Biotechnology, Santa Cruz, Calif) by incubat-
ing in the primary antibody, followed by a horseradish
peroxidase-conjugated secondary antibody 1:1000 (cata-
log noM15345 for NOS; Transduction Laboratories, Lex-
ington, Ky and catalog no 7074 for actin; Cell Signaling
Technology, Inc, Beverly, Mass). Blots were visualized
using the western lightning chemiluminescence reagent
(PerkinElmer Life Science, Inc, Boston,Mass) according to
the manufacturer’s directions, and were exposed to x-ray
Table I. Primer sequences of NOS isoforms and -actin
nNOS forward primer 5=-TT
nNOS reverse primer 5=-AG
iNOS forward primer 5=-TC
iNOS reverse primer 5=-CC
eNOS forward primer 5=-TG
eNOS reverse primer 5=-TC
-actin forward primer 5=-CC
-actin reverse primer 5=-GCfilm.Reverse transcription polymerase chain reaction
(RT-PCR). nNOS, eNOS and iNOS mRNA were de-
tected in the occluded zone of the brain by RT-PCR, as
previously described.19 Total RNA was extracted from the
brain tissue with RNaseMaxi kits (Qiagen, Valencia, Calif).
First strand cDNA synthesis was then performed with the
use of 5 g of total RNA, oligo (dT) primer (BRL), and
Superscript III Reverse Transcriptase (Invitrogen, Carls-
bad, Calif) according to manufacturer’s instructions.
RT-PCR was carried out in O’ in 1DNA polymerase solu-
tion at 50°C for 60 minutes followed by enzyme inactiva-
tion at 72°C for 15 minutes. The primer sequences are
shown in Table I. The amplification procedure consisted of
initial denaturation at 95°C for 5 minutes, following cycle
parameters of denaturation at 95°C for 1minute, annealing
at 60°C for 1 minute, and extension at 72°C for 1 minute
for 35 cycles. The amplified products were separated gel
electrophoresis in 1.5% agarose gel containing 0.5 mg/ml
ethidium bromide. Each set of PCRs included control
samples run without RNA or in which the RT step was
omitted. The RT-PCR procedure was highly reproducible
under the present experimental conditions.
Malondialdehyde assay. Malondialdehyde (MDA)
levels were measured by using thiobarbituric acid method
described by Okhawa.24 Briefly, brain tissues were homog-
enized with 10 times (w/v) sodium phosphate buffer. The
reagents of 1.5ml 20% of acetic acid, 0.2ml 8.1% of sodium
dodecyl sulfate, 1.5 ml 0.8% of thiobarbituric acid was
added to 0.1ml tissue sample. Themixture was then heated
at 100°C for 60 minutes. After cooling, 1.0 ml distilled
water and 5.0 ml of the mixture of n-butanol and pyridine
was added and centrifuged. The organic layer was with-
drawn and measured at 532 nm. MDA concentrations in
the samples were calculated by a standard calibration curve
by using 1,1,3,3-tetramethoxypropane prepared in the
same manner. Each measurement was performed in dupli-
cate. MDA concentration was expressed as nanomoles per
gram tissue weight.
Drug administration. Resveratrol (Sigma) was dis-
solved in 40% (v/v) propylene glycol to the desired con-
centrations in normal saline. Final concentration of pro-
pylene glycol in the resveratrol solution was 4  103%
(v/v). At this concentration, propylene glycol had no effect
on the infarct size of focal cerebral ischemia. In this study,
Primer sequence
AAGCTTCTGGCAACAGCGACAATTT-3=
AAGGCGGTTGGTCACTTC-3=.
ACACCCTTCACCACAA-3=.
CTCCTGCCCACTTCCTC-3=
AGCATCACCTACGA-3=.
AGCATCAAATACCT-3=.
GCAAGAGAGGCATCCTG-3=
TAGTGATGACCTGACCGT-3=CCG
ATCT
ACG
ATC
GGC
CCG
AGAresveratrol solution of 0.3 ml was administered at three
a.
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vein when the common carotid arteries clips were removed.
Rats injected with 0.3 ml vehicle, 4  103% (v/v) pro-
pylene glycol in normal saline, were used as controls. Sham
operated animals underwent all surgical procedure except
MCA ligation. For examining which NOS was responsible
for the neuroprotective effect of resveratrol in FCI injury,
we administrated a nonselective NOS inhibitor (L-NAME,
1 mg/kg),25 a selective nNOS inhibitor (7-nitroindazole,
50 mg/kg),26 a specific iNOS inhibitor (S-methylisothiourea
sulfate, 3 mg/kg),27 and a selective eNOS inhibitor
(L-NIO, 10 mg/kg)28 15 minutes before MCA occlusion
to examine their antagonistic effect with resveratrol. Ani-
mals were randomly allocated to each drug treatment and
control groups.
Statistics. Data are expressed as mean  standard
error of mean (SEM). Statistical analysis of differences in
plasma LDH and NO levels, physiological measurements,
infarct volume between vehicle and drug treated groups
were carried out by one-way analysis of variance (ANOVA)
for combined data and followed by unpaired, two-tailed
Student t test. P  .05 was considered to be statistically
significant.
RESULTS
Plasma LDH levels. Cellular damage was evaluated
by measuring the LDH level in plasma at the end period of
focal cerebral ischemia. The effects of resveratrol on LDH
activity are shown in Table II. Low LDH activity was seen
in sham-operated animals (91.5  28.7 U/L) (n  7)
before occlusion. In the operated animals without resvera-
trol treatment, large increase in the LDH activity was
observed in the plasma (267.7  36.3 U/L) (n  7). In
contrast, administration of resveratrol attenuated LDH
release during 1 hour MCA occlusion and 24 hour reper-
fusion. Resveratrol at the dose of 1g/kg reduced the LDH
activity to 105.4 29.3 U/L (n7). The effect of (259.8
41.6 mm3 [n  7]) and L-NIO (233.8  28.5 mm3
[n  7]), but had no influence when pretreatment
with 7-nitroindazole (138.0  29.7 mm3 [n   7]) or
Table II. LDH (U/L) and NO (mol/L) release in the p
Treatment
Sham
Vehicle
Resveratrol 0.01 g/kg
0.1 g/kg
1 g/kg
L-NAME 1 mg/kg  resveratrol 1 g/kg
7-nitroindazole 50 mg/kg  resveratrol 1 g/kg
S-methylisothiourea 3 mg/kg  resveratrol 1 g/kg
L-NIO 10 mg/kg  resveratrol 1 g/kg
Values are expressed as mean  SEM of seven rats.
Vehicle is 4103% (v/v) propylene glycol in normal saline.
NO release was measured by the presence of nitrite and nitrate in the plasm
*P  .05 compared with vehicle group.S-methylisothiourea sulfate (160.2  31.2 mm3 [n  9]).Plasma NO. The effects of resveratrol on resveratrol
on decreased LDH release was blocked by pretreatment
with L-NAME NO contents are shown in Table II. NO
release was measured by the presence of nitrite (NO2
) and
nitrate (NO3
) in plasma. The NO content in sham-
operated rats was 7.35  1.41 mol/L (n  7). In the
operated animals without resveratrol treatment, the NO
content in plasma of rats was 12.26 1.21 mol/L (n 7).
Administration of resveratrol increases the NO release in a
dose-dependent manner during 1 hour MCA occlusion
and 24 hour reperfusion. Resveratrol at the dose of
1 g/kg, the plasma NO was increased to 25.70 
4.28 mol/L (n  7). However, L-NAME, 7-nitroindazole,
S-methylisothiourea sulfate, and L-NIO decrease the effect
of resveratrol on upregulation of NO release.
Protein levels of NOS. It was noticed that the levels
of iNOS, eNOS, and nNOS proteins in either nonoccluded
zone or occluded zone of sham-operated rats were similar.
As shown in Fig 1, the density of NOS protein expression
was normalized with -actin from the same samples. Focal
cerebral ischemia induced iNOS expression and administra-
tion resveratrol at the dose of 1 g/kg significantly sup-
pressed iNOS induction in the occluded zone. In contrast,
administration 1 g/kg resveratrol significant increased
the eNOS expression in the occluded zone compared with
vehicle-treated group. The protein level of nNOS expres-
sion was not significantly different with or without resvera-
trol treatment after focal cerebral ischemia between nonoc-
cluded and occluded brain tissue. Fig 1 is representative of
seven different experiments.
NOS mRNA expression. Resveratrol at the dose of
1 g/kg reduced the iNOSmRNA signal in occluded zone
compared with the vehicle-treated group. However, ad-
ministration of 1 g/kg resveratrol increased eNOS
mRNA expression in occluded zone compared with the
vehicle-treated group. There was no influence on nNOS
mRNA expression in non-occluded zone and occluded
zone between resveratrol-treated group and vehicle-treated
group (Fig. 2). Fig 2 is representative of seven different
a during focal cerebral ischemia
n LDH NO
7 91.5  28.7 7.4  1.4
12 267.7  36.3 12.3  1.2
7 188.6  23.5 13.9  1.8
7 99.2  19.4* 20.3  1.6*
10 105.4  29.3* 25.7  4.3*
9 259.8  41.6 11.2  0.8
11 138.0  29.7* 14.0  1.9
9 160.2  31.2* 16.2  3.0
9 233.8  28.5 14.8  1.4lasmexperiments.
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MCA occlusion and 24-hour reperfusion are shown in Fig. 3.
Focal cerebral ischemia resulted in significantly increased
Fig 1. Western blot analyses of brain tissue after FCI injury for
iNOS, eNOS, nNOS, and -actin in rats. Rats were treated with
vehicle or resveratrol at a dose of 1 g/kg when the common carotid
arteries clips were removed. Data were normalized with -actin and
expressed as percentage rate. Each value represents the mean of seven
individual experiments. Results are expressed as mean SEM. *P
.05 compared with vehicle group. S  sham group, non-ischemic
operated rats; V vehicle-treated group; R resveratrol-treated group.levels of MDA in the group treated with vehicle (394.0 38.6 nmol/g wet tissue) comparedwith shamgroup (127.8
26.8 nmol/g wet tissue). MDA levels in the resveratrol
treated groups were decreased in a dose-dependent man-
ner. Resveratrol at the dose of 1 g/kg significantly re-
duced the MDA level to 157.3  31.3 nmol/g wet tissue.
Fig 2. Analysis of iNOS, eNOS, nNOS, and -actin mRNA
expression of brain tissue in rats after FCI injury. Rats were treated
with vehicle or resveratrol at a dose of 1 g/kg when the common
carotid arteries clips were removed. S sham group, non-ischemic
operated rats; V  vehicle-treated group; R  resveratrol-treated
group.
Fig 3. Effect of resveratrol in the levels of MDA on FCI injury
rats. Each experimental group is seven rats. Values are expressed as
mean  SEM. *P  .05 compared with vehicle group.Each group is seven rats.
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volume are shown in Fig. 4. The middle cerebral artery was
occluded for 1 hour and then reperfused for 24 hours; the
infarct volumes in the rats were 150.9  15.1 mm3 (n 
12). If 1 g/kg resveratrol was treated immediately after
release of the common carotid arteries clips, the infarct
volume in rats significantly reduced to 42.8  11.8 mm3
(n  10). The effect of resveratrol on decreased infarct
volume was completely blocked by pretreatment with
L-NAME (147.8  31.8 mm3 [n  9]) and L-NIO (110.5 
21.1 mm3 [n  9]), but had no influence when pretreat-
ment with 7-nitroindazole (58.6  16.1 mm3 [n   11]) or
S-methylisothiourea sulfate (71.9  17.0 mm3 [n  9]).
DISCUSSION
In this study, we demonstrated that treatment with
resveratrol, at the doses of 0.1 and 1 g/kg, significantly
decreased LDH levels in the femoral blood on rats after
FCI injury. The observation in Table I showed that the
resveratrol at the dose of 0.1 g/kg seemed more effective
than 1g/kg, but the difference did not a reach statistically
significant level. The LDH activity in plasma was an indi-
cator of cellular damage. The decreasing of LDH activity
after resveratrol administration suggested that resveratrol
might reduce the neuronal damages elicited after FCI
injury. This result was consistent with the finding of our
previously study, which showed that resveratrol suppressed
the total infarct volume in rats subjected to FCI injury.16
The result indicated that resveratrol possessed robust neu-
Fig 4. Effect of NOS inhibitors on the neuroprotective effect of
resveratrol in FCI injury rats. Each experimental group is seven rats.
Values are expressed as mean  SEM. *P  .05 compared with
vehicle group. #P .05 compared with resveratrol group. L-NAME
(1mg/kg; i.v.): nonselective NOS inhibitor. 7-nitroindazole (50 mg/
kg; i.p.): nNOS selective inhibitor. S-methylisothiourea: (3 mg/kg;
i.p.): iNOS selective inhibitor. L-NIO (10mg/kg; i.p.): eNOS selec-
tive inhibitor.roprotective effect against FCI in rats.In addition, our results revealed that the NO contents in
plasma were significantly increased with a dose-dependent
manner in resveratrol-treated group compared with vehicle-
treated group in rats after FCI injury. NO is a small, gas-
eous, biologically active messenger with a wide rage of
physiological and pathological actions.3 NO possesses va-
sodilator effect,4 anti-inflammatory activity,7 and anti-
platelet activity.5,6 All these physiological effects of NO
seem to have a beneficial role during FCI injury. However,
it has been reported that the interaction between NO and
superoxide radicals generates peroxynitrite, a potent free
radical that could induce lipid peroxidation of cellular
membranes.3 Current studies indicate that NO plays a dual
role, and may have protective or toxic effect on brain tissue
under FCI injury, depending on its source. NO is produced
by a family of isoenzymes termed of NOS.4 The eNOS and
nNOS are present under physiological conditions, whereas
the iNOS is expressed in response to immunological stim-
ulation. Among the three isoforms of NOS, eNOS pro-
duces NOwith beneficial effects, such as vasodilative effect,
anti-platelet aggregation effect, and inhibit PMN adhesion,
whereas nNOS and iNOS produce NO with deleterious
effects. Overproduction of NO from either nNOS or iNOS
leads to neurodegeneration.29 This receives further support
from the evidence of the reduction of brain edema and
infarction volume in nNOS or iNOS knockout mice after
FCI injury.30,31 In this study, we found that iNOS protein
was induced in the rat brain tissue after FCI injury. Treat-
ment with resveratrol suppressed iNOS protein expression
in the same condition. Whereas, treated with resveratrol
significantly increased eNOS protein expression in brain
tissue after FCI injury compared with vehicle-treated group
in rats. But there was no significant difference in nNOS
protein expression between resveratrol-treated group and
vehicle-treated group. Further study showed that a similar
result on mRNA expression. Resveratrol downregulated
iNOS mRNA expression, upregulated eNOS mRNA ex-
pression, and had no influence on nNOS mRNA expres-
sion. These results suggest that the effects of resveratrol on
iNOS and eNOS expression were through transcription.
Although the iNOS produces more NO compared with
eNOS, we found that the NO content in plasma was
significantly increased in resveratrol-treated group in this
study. It may due to the delayed appearance of iNOS in
cerebral ischemic injury. Unlike eNOS and nNOS, iNOS is
not a constitutive enzyme, and is produced after the cyto-
kine stimulation of neutrophils resulting from ischemia.
Messenger RNA of iNOS is detectable 12 hours after
ischemia.32
Resveratrol is a naturally polyphenolic compound that
possesses antioxidant properties. Indeed, we found that
administration of resveratrol decreased MDA, a lipid per-
oxidation product is considered a presumptive marker for
oxidative stress, in a dose-dependent manner in brain tissue
after FCI injury. It is suggested that resveratrol reduced the
oxidative stress on rats due to FCI injury. A number of
studies have demonstrated the role of free radicals on the
injury of FCI.33 The antioxidant activity of resveratrol may
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injury from the interaction of superoxide anion and NO in
dose-dependent manner. NO is known as a vasodilator,4
inhibits platelet aggregation,5 and adds platelet6 and
PMN7 to the vascular endothelium, which are beneficial for
the improvement of FCI injury.
To investigate which NOS was responsible for the
neuroprotective effect of resveratrol in rats after FCI
injury, we administrated a nonselective NOS inhibitor
(L-NAME), a selective nNOS inhibitor (7-nitroindazole),
a specific iNOS inhibitor (S-methylisothiourea sulfate), and
a selective eNOS inhibitor (L-NIO), 15 minutes prior
to MCA occlusion to examine their antagonistic effects
with resveratrol. Whether 7-nitroindazole inhibit both
nNOS and eNOS have generated considerable debate, the
IC50 values for inhibition of nNOS and eNOS are similar
in vitro.34 But 7-nitroindazole does not influence the
endothelium-dependent relaxation of blood vessels in vivo.
Coert reported that 7-nitroindazole in a dose range from
0.1 to 100 mg/kg inhibited nNOS without alterations in
MABP.25 Thus, it is considered that 7-nitroindazole does
not affect eNOS activity in vivo. Based on this finding,
many investigators use 7-nitroindazole as a nNOS inhibi-
tor.26,35 In this study, the dose of 7-nitroindazole was 50
mg/kg, which is considering as a selective nNOS inhibitor.
On the other hand, Wolff reported that L-NIO was the
most potent in inhibiting the eNOS with an IC50 value of
0.08 M, a value approximately four-fold lower than that
observed for the iNOS and nNOS.36 L-NIO reduces rest-
ing cyclic GMP levels and constricts pial arteries, both
consistent with eNOS contributes to resting vascular
tone.37 In addition, L-NIO significantly inhibits the hypo-
tensive responses to acetylcholine and bradykinin in anes-
thetized rats.38 Based on this finding, several studies use
L-NIO as an eNOS inhibitor.28,35 Our studies found that
nNOS and iNOS inhibitors did not act against resveratrol
to augment the infarct volume. However, administration of
nonselective NOS inhibitor or selective eNOS inhibitor
completely blocked the decreased infarction effect of res-
veratrol. The results suggested that eNOS and iNOS, but
not nNOS, may be involved in the neuroprotective effect of
resveratrol in rats subjected to FCI injury and NO plays a
crucial role in the effects.
In this study, we present the evidence that resveratrol
increases NO production, attenuates the free radicals, and
significantly protects rats brain tissue against FCI injury.
This study was supported by grant NSC 95-2314-B-
303-019, NSC 95-2314-B-303-024, and NSC 95-2320-
B-040-027 from the National Science Council and Aca-
demic Sinica to Dr S. K. Tsai and Dr S. S. Huang. The
authors thank Chun-Lien Chih for technical support.
AUTHOR CONTRIBUTIONS
Conception and design: S-KT, L-MH, S-SH
Analysis and interpretation: L-MH, HC, M-WN, H-YL,
S-SH
Data collection: HC, M-WN, H-YL, FB-YZWriting the article: S-KT, L-MH, Y-TF, S-SH
Critical revision of the article: S-KT, L-MH, HC, S-SH
Final approval of the article: S-KT, L-MH, S-SH
Statistical analysis: Y-TF, HC, M-WN, H-YL, FB-YZ,
S-SH
Obtained funding: S-KT, S-SH
Overall responsibility: S-KT, L-MH, S-SH
S-KT and L-MH contributed equally to this work.
REFERENCES
1. Moncada S, Higgs A. The L-arginine/nitric oxide pathway. N Engl
J Med 1993;329:2002-6.
2. Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: struc-
ture, function and inhibition. Biochem J 2001;357:593-615.
3. Moncada S, Palmer RM, Higger EA. Nitric oxide: physiology, pathol-
ogy, and pharmacology. Pharmacol Rev 1991;43:109-42.
4. Faraci FM, Brian JE Jr. Nitric oxide and the cerebral circulation. Stroke
1994;25:692-703.
5. Riddell DR, Owen JS. Nitric oxide and platelet aggregation. Vitam
Horm 1999;57:25-48.
6. Konishi R, Shimiz R, Firestone L, Walters FR, Wagner WR, Federspiel
WJ, et al. Nitric oxide prevents human platelet adhesion to fiber
membranes in whole blood. ASAIO J 1996;42:M850-3.
7. Secco DD, Paron JA, de Oliveira SH, Ferreira SH, Silva JS, Cunha Fde
Q. Neutrophil migration in inflammation: nitric oxide inhibits rolling,
adhesion and induces apoptosis. Nitric Oxide 2003;9:153-64.
8. Zhang F, Iadecola C. Nitroprusside improves blood flow and reduces
brain damage after focal ische0mia. Neuroreport 1993;4:559-62.
9. Morikawa E, Moskowitz MA, Huang Z, Yoshida T, Irikura K, Dalkara
T. L-arginine infusion promotes nitric oxide-dependent vasodilation,
increases regional cerebral blood flow, and reduces infarction volume in
the rat. Stroke 1994;25:429-35.
10. Soleas GJ, Diamandis EP, Goldberg DM. Wine as a biological fluid:
history, production, and role in disease prevention. J Clin Lab Anal
1997;11:287-313.
11. Frankel EN, Waterhouse AL, Kinsella JE. Inhibition of human LDL
oxidation by resveratrol. Lancet 1993;341:1103-4.
12. Shin NH, Ryu SY, Lee HS, Min KR, Kim YS. Inhibitory effects of
hydroxystilbenes on cyclooxygenase from sheep seminal vesicles. Planta
Med 1998;64:283-4.
13. Bertelli AA, Giovannini L, Giannessi D,Migliori M, Bernini W, Fregoni
M, et al. Antiplatelet activity of synthetic and natural resveratrol in red
wine. Int J Tissue React 1995;17:1-3.
14. Chen CK, Pace-Asciak CR. Vasorelaxing activity of resveratrol and
quercetin in isolate rat aorta. Gen Pharmacol 1996;27:363-6.
15. Rotondo S, Rajtar G,Manarinis S, Celardo A, Rotillio D, de GaetanoG,
et al. Effect of trans-resveratrol, a natural polyphenolic compound, on
human polymorphonuclear leukocyte function. Brit J Pharmacol 1998;
123:1691-9.
16. Huang SS, Tsai MC, Chih CL, Hung LM, Tsai SK. Resveratrol reduc-
tion of infarct size in Long-Evans rats subjected to focal cerebral
ischemia. Life Sci 2001;69:1057-65.
17. Kiziltepe U, Turan NN, Han U, Ulus AT, Akar F. Resveratrol, a red
wine polyphenol, protects spinal cord from ischemia-reperfusion injury.
J Vasc Surg 2004;40:138-45.
18. Chander V, Chopra K. Role of nitric oxide in resveratrol-induced renal
protective effects of ischemic preconditioning. J Vasc Surg 2005;42:
1198-1205.
19. Hung LM, Su MJ, Chen JK. Resveratrol protects myocardial ischemia-
reperfusion injury through both NO-dependent and NO-independent
mechanisms. Free Radical Bio Med 2004;36:774-81.
20. Huang SS, Tsai SK, Chih CL, Chiang LY, Hsieh HM, Teng CM, et al.
Neuroprotective effect of hexasulfobutylated C60 on rats subjected to
focal cerebral ischemia. Free Radical Bio Med 2001;30:643-9.
21. Bergmeyer HU, Brent E. UV-assay with pyruvate and NADH. In:
Bergmeyer, HU, editor. Methods of enzymatic analysis. New York:
Academic Press; 1974; p. 574-9.
JOURNAL OF VASCULAR SURGERY
Volume 46, Number 2 Tsai et al 35322. Archer J. Measurement of nitric oxide in biological models. FASEB J
1993;7:349-60.
23. Karabiyikoglu M, Han HS, Yenari MA, Steinberg GK. Attenuation of
nitric oxide synthase isoform expression by mild hypothermia after focal
cerebral ischemia: variations depending on timing of cooling. J Neuro-
surg 2003;98:1271-6.
24. Okhawa H, Ohishi N, Yagi K. Assay of lipid peroxides in animals tissue
by thiobarbituraic acid reaction. Anal Biochem 1979;95:351-8.
25. Coert BA, Anderson RE, Meyer FB. A comparative study of the effects
of two nitric oxide synthase inhibitors and two nitric oxide donors on
temporary focal cerebral ischemia in the Wistar rat. J Neurosurg 1999;
90:332-8.
26. Gursoy-Ozdemir Y, Bolay H, Sariba O, Dalkara T. Role of endothelial
nitric oxide generation and peroxynitrite formation in reperfusion in-
jury after focal cerebral ischemia. Stroke 2000;31:1974-81.
27. Maksimovich NE, Zinchuk VV, Maslakov DA. The degree of oxidative
stress in the rat brain during ischemia and reperfusion in conditions of
correction of the L-arginine-NO system. Neurosci Behav Physiol 2006;
36:373-8.
28. Shen J, Ma S, Chan P, Lee W, Fung PC, Cheung RT, et al. Nitric oxide
down-regulates caveolin-1 expression in rat brains during focal cerebral
ischemia and reperfusion injury. J Neurochem 2006;96:1078-89.
29. Samdani AF, Dawson TM,Dawson VL. Nitric oxide synthase in models
of focal ischemia. Stroke 1997;28:1283-8.
30. Hara H, Huang PL, Panahian N, Fishman MC, Moskowitz MA.
Reduced brain edema and infarction volume in mice lacking the neu-ronal isoform of nitric oxide synthase after transient MCA occlusion.
J Cereb Blood Flow Metab 1996;16:605-11.
31. Iadecola C, Zhang F, Casey R, Nagayama M, Ross ME. Delayed
reduction of ischemic brain injury and neurologic deficits in mice
lacking the inducible nitric oxide synthase gene. J Neurosci 1997;17:
9157-64.
32. O’Mahony D, Kendall MJ. Nitric oxide in acute ischemic stroke: a target
for neuroprotection. J Neurol Neurosurg Psychiatry 1999;67:1-3.
33. Love S. Oxidative stress in brain ischemia. Brain Pathol 1999;9:119-31.
34. Bland-Ward PA, Moore PK. 7-Nitro indazole derivatives are potent
inhibitors of brain, endothelium and inducible isoforms of nitric oxide
synthase. Life Sci 1995;57:PL131-5.
35. Jiang MH, Kaku T, Hada J, Hayashi Y. Different effects of eNOS and
nNOS inhibition on transient forebrain ischemia. Brain Res 2002;946:
139-47.
36. Wolff DJ, Lubeskie A, Gauld DS, Neulander MJ. Inactivation of nitric
oxide synthases and cellular nitric oxide formation by N6-iminoethyl-
L-lysine and N5-iminoethyl-L-ornithine. Eur J Pharmacol 1998;350:
325-34.
37. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, patho-
physiology, and pharmacology. Pharmacol Rev 1991;43:109-42.
38. Rees DD, Palmer RM, Schulz R, Hodson HF, Moncada S. Character-
ization of three inhibitors of endothelial nitric oxide synthase in vitro
and in vivo. Br J Pharmacol 1990;101:746-52.Submitted Oct 5, 2006; accepted Apr 16, 2007.
